Loading organizations...
Key people at Gecko Health.
Gecko Health was founded in 2012 by Yechiel Engelhard (Founder, CEO).
Cambridge, Massachusetts-based Gecko Health Innovations develops software and hardware solutions designed to improve medication compliance and adherence management for patients suffering from chronic respiratory diseases. The company's flagship product, CareTRx, operates as a cloud-based platform featuring a hardware sensor that attaches directly to metered-dose inhalers alongside a companion software application. This connected health system enables patients, caregivers, and medical professionals to track real-time adherence data for conditions such as asthma and chronic obstructive pulmonary disease. Prior to its acquisition by Teva Pharmaceutical Industries Ltd. in a definitive agreement announced in September 2015, the enterprise successfully filed 11 patents focused on clinical pharmacology, diodes, and healthcare quality. Originating as the winning team from an MIT Media Lab health and wellness innovation event, the company was founded in 2012 by Dr. Yechiel Engelhard and Mark Maalouf.
Gecko Health was founded in 2012 by Yechiel Engelhard (Founder, CEO).
Key people at Gecko Health.
Gecko Health Innovations is a connected health company that develops smart hardware and software solutions to help patients better manage chronic respiratory conditions such as asthma and COPD. Their product ecosystem includes sensors for inhalers paired with a smartphone app that collects, synchronizes, and presents medication usage data in an intuitive way, promoting adherence and improved disease management. The company serves patients, caregivers, and healthcare providers by enabling better communication and data-driven insights to support respiratory disease management. Gecko Health has demonstrated growth momentum culminating in its acquisition by Teva Pharmaceutical Industries, a global leader in pharmaceuticals, which aims to integrate Gecko’s technology with its respiratory product portfolio[1][3].
Founded in 2012 in Cambridge, Massachusetts, Gecko Health Innovations was established by Dr. Yechiel Engelhard, who envisioned a platform that connects chronic medication management into one system to empower patients through real-time data and clinical knowledge. The idea emerged from the need to improve adherence and outcomes in respiratory diseases by leveraging connected devices and behavioral tools. Early traction came from developing a reliable system that intuitively connects patients, caregivers, and families, which aligned well with healthcare and pharmaceutical industry needs. This vision attracted Teva Pharmaceuticals, which acquired Gecko to reinforce its leadership in respiratory care[1].
Gecko Health rides the growing trend of digital health and connected medical devices aimed at improving chronic disease management through real-world data and patient engagement. The timing is favorable due to increasing healthcare emphasis on remote monitoring, medication adherence, and personalized care, especially for chronic respiratory conditions that impose significant health burdens globally. Market forces such as rising prevalence of asthma and COPD, healthcare cost containment pressures, and advances in IoT and mobile health technologies support Gecko’s solutions. By integrating behavioral science with technology, Gecko influences the broader ecosystem by demonstrating how connected health can enhance outcomes and reduce costs in chronic disease management[1][3].
Post-acquisition by Teva, Gecko Health is positioned to scale its impact by embedding its connected health platform within a global pharmaceutical leader’s respiratory care offerings. Future trends shaping its journey include expanded use of digital therapeutics, AI-driven personalized interventions, and broader adoption of remote patient monitoring. Gecko’s influence may evolve from a niche connected device provider to a key enabler of integrated, data-driven respiratory care solutions worldwide, contributing to improved patient adherence and health outcomes on a large scale. This trajectory underscores the growing convergence of pharmaceuticals, digital health, and patient-centric care models[1].
